P21 codon 31 polymorphism associated with cancer among white people: Evidence from a meta-analysis involving 78 074 subjects

Mutagenesis

Volumn 26, Issue 4, 2011, Pages 513-521

  Liu, Fei ^a   Li, Bo ^a   Wei, Yonggang ^a   Chen, Xi ^a   Ma, Yu ^a   Yan, Lvnan ^a   Wen, Tianfu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROTEIN P21; SERINE DERIVATIVE;

ALLELE; ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CLINICAL ASSESSMENT; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ESOPHAGUS CANCER; ETHNICITY; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NEOPLASM; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK; RISK FACTOR; STOMACH CANCER;

CODON; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PUBLICATION BIAS; RISK FACTORS;

EID: 79959720769     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ger010     Document Type: Article

References (68)

1. Hartwell, L. H. and Kastan, M. B. (1994) Cell cycle control and cancer. Science, 266, 1821-1828.
2. Sherr, C. J. (1996) Cancer cell cycles. Science, 274, 1672-1677.
3. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704. (Pubitemid 24036020)
4. Li, R., Waga, S., Hannon, G. J., Beach, D. and Stillman, B. (1994) Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature, 371, 534-537. (Pubitemid 24306614)
5. El-Deiry, W. S., Tokino, T., Velculescu, E. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825. (Pubitemid 23346378)
6. Li, G., Liu, Z., Sturgis, E. M., Shi, Q., Chamberlain, R. M., Spitz, M. R. and Wei, Q. (2005) Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 26, 1596-1602. (Pubitemid 41236053)
7. Roninson, I. B. (2002) Oncogenic functions of tumour suppressor p21 (Waf1/Cip1/Sdi1): association with cell senescence and tumour promoting activities of stromal fibroblasts. Cancer Lett., 179, 1-14.
8. Mousses, S., Ozcelik, H., Lee, P. D., Malkin, D., Bull, S. B. and Andrulis, I. L. (1995) Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet., 4, 1089-1092.
9. Ebner, F., Schremmer-Danninger, E. and Rehbock, J. (2010) The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort. J. Cancer Res. Clin. Oncol., 136, 1369-1375.
10. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. (2010) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res. Treat., 120, 727-736.
11. Xu, Y. J., Ge, Y. L., Zhang, J. Y., Li, F. N. and Zheng, Z. (2010) Polymorphism of COMT, p21 and NuMA in sporadic breast cancer. Zhong Hua Lin Chuang Yi Shi Za Zhi, 4, 591-596.
12. Zhu, M., Huang, T. S. and Zhao, J. J. (2007) P53PN3 and P21WAF1 gene polymorphisms associated with breast cancer among Chinese Han women in Guizhou regions. Chinese J. Clin. Lab. Sci., 25, 373-374.
13. Cox, A., Dunning, A. M., Garcia-Closas, M. et al. (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet., 39, 352-358.
14. Ma, H., Jin, G., Hu, Z. et al. (2006) Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women. Int. J. Cancer., 119, 2173-2178.
15. Keshava, C., Frye, B. L., Wolff, M. S., McCanlies, E. C. and Weston, A. (2002) Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol. Biomarkers Prev., 11, 127-130.
16. Jiang, P., Liu, J., Li, W., Zeng, X. and Tang, J. (2010) Role of p53 and p21 polymorphisms in the risk of cervical cancer among Chinese women. Acta Biochim. Biophys. Sin. (Shanghai), 42, 671-676.
17. Roh, J. W., Kim, B. K., Lee, C. H. et al. (2010) P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol. Res., 18, 453-459.
18. Tian, Q., Lu, W., Chen, H., Ye, F. and Xie, X. (2009) The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. Int. J. Gynecol. Cancer., 19, 1011-1014.
19. Yang, A., Zheng, X., Tao, L. et al. (2008) Studies on correlation between p21Ser31Arg, p53Arg72Pro Polymorphisms and cervical carcinoma in Uigur Women in Xinjiang. J. Shihezi Univ. (Nat. Sci.), 26, 6-11.
20. Bhattacharya, P. and Sengupta, S. (2005) Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women. Gynecol. Oncol., 99, 176-182.
21. Lee, S. A., Kim, J. W., Roh, J. W., Choi, J. Y., Lee, K. M., Yoo, K. Y., Song, Y. S. and Kang, D. (2004) Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women. Gynecol. Oncol., 93, 14-18.
22. Lee, J. E., Lee, S. J., Namkoong, S. E., Um, S. J., Sull, J. W., Jee, S. H., You, Y. K. and Park, J. S. (2004) Gene-gene and gene-environmental interactions of p53, p21, and IRF-1 polymorphisms in Korean women with cervix cancer. Int. J. Gynecol. Cancer., 14, 118-125.
23. Roh, J., Kim, M., Kim, J., Park, N., Song, Y., Kang, S. and Lee, H. (2001) Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. Cancer Lett., 165, 59-62. (Pubitemid 32206658)
24. Choi, Y. Y., Kang, H. K., Choi, J. E. et al. (2008) Comprehensive assessment of P21 polymorphisms and lung cancer risk. J. Hum. Genet., 53, 87-95.
25. Popanda, O., Edler, L., Waas, P. et al. (2007) Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer, 55, 25-34. (Pubitemid 46038874)
26. Su, L., Sai, Y., Fan, R. et al. (2003) P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer, 40, 259-266.
27. Su, L., Liu, G., Zhou, W., Xu, L. L., Miller, D. P., Park, S., Lynch, T. J., Wain, J. C. and Christiani, D. C. (2003) No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 12, 174-175.
28. Shih, C. M., Lin, P. T., Wang, H. C., Huang, W. C. and Wang, Y. C. (2000) Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn. J. Cancer Res., 91, 9-15.
29. Själander, A., Birgander, R., Rannug, A., Alexandrie, A. K., Tornling, G. and Beckman, G. (1996) Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum. Hered., 46, 221-225.
30. Taghavi, N., Biramijamal, F., Abbaszadegan, M. R., Khademi, H., Sotoudeh, M. and Khoshbakht, S. (2010) P21(waf1/cip1) gene polymorphisms and possible interaction with cigarette smoking in esophageal squamous cell carcinoma in northeastern Iran: a preliminary study. Arch. Iran. Med., 13, 235-242.
31. Yang, W., Qi, Q., Zhang, H. et al. (2010) p21 Waf1/Cip1 polymorphisms and risk of esophageal cancer. Ann. Surg. Oncol., 17, 1453-1458.
32. Wu, M. T., Wu, D. C., Hsu, H. K., Kao, E. L., Yang, C. H. and Lee, J. M. (2003) Association between p21 codon 31 polymorphism and esophageal cancer risk in a Taiwanese population. Cancer Lett., 201, 175-180.
33. Lai, K. C., Chen, W. C., Jeng, L. B., Li, S. Y., Chou, M. C. and Tsai, F. J. (2005) Association of genetic polymorphisms of MK, IL-4, p16, p21, p53 genes and human gastric cancer in Taiwan. Eur. J. Surg. Oncol., 31, 1135-1140.
34. Xi, Y. G.,Ding,K.Y., Su,X. L., Chen,D. F., You, W. C., Shen, Y. andKe, Y. (2004) p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis, 25, 2201-2206.
35. Wu, M. T., Chen, M. C. and Wu, D. C. (2004) Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett., 205, 61-68.
36. Cacina, C., Yaylim-Eraltan, I., Arikan, S., Saglam, E. K., Zeybek, U. and Isbir, T. (2010) Association between CDKN1A Ser31Arg and C20T gene polymorphisms and colorectal cancer risk and prognosis. In Vivo, 24, 179-183.
37. Liu, B., Zhang, Y., Jin, M., Ni, Q., Liang, X., Ma, X., Yao, K., Li, Q. and Chen, K. (2010) Association of selected polymorphisms of CCND1, p21, and caspase8 with colorectal cancer risk. Mol. Carcinog., 49, 75-84.
38. Polakova, V., Pardini, B., Naccarati, A. et al. (2009) Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum. Mutat., 30, 661-668.
39. Roh, J. W., Kim, J. W., Park, N. H., Song, Y. S., Park, I. A., Park, S. Y., Kang, S. B. and Lee, H. P. (2004) p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol. Oncol., 93, 499-505.
40. Hachiya, T., Kuriaki, Y., Ueoka, Y., Nishida, J. and Kato, K. (1999) Wake N.WAF1 genotype and endometrial cancer susceptibility. Gynecol. Oncol., 72, 187-192.
41. Rodrigues, F. C., Kawasaki-Oyama, R. S., Fo, J. F., Ukuyama, E. E., Antonio, J. R., Bozola, A. R., Romeiro, J. G., Rahal, P. and Tajara, E. H. (2003) Analysis of CDKN1A polymorphisms markers of cancer susceptibility? Cancer Genet. Cytogenet., 142, 92-98.
42. Gomes, C. C., Drummond, S. N., Guimarães, A. L., Andrade, C. I., Mesquita, R. A. and Gomez, R. S. (2008) P21/WAF1 and cyclin D1 variants and oral squamous cell carcinoma. J. Oral Pathol. Med., 37, 151-156.
43. Bau,D.T., Tsai,M.H., Lo,Y.L., Hsu,C.M.,Tsai, Y.,Lee,C.C. andTsai,F. J. (2007) Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients. Anticancer Res., 27, 1559-1564.
44. Konishi, R., Sakatani, S., Kiyokane, K. and Suzuki, K. (2000) Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors. J. Dermatol. Sci., 24, 177-183.
45. Hishida, A., Matsuo, K., Tajima, K., Ogura, M., Kagami, Y., Taji, H. et al. (2004) Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese. Leuk. Lymphoma., 45, 957-964.
46. Johnson, G. G., Sherrington, P. D., Carter, A., Lin, K., Liloglou, T., Field, J. K. and Pettitt, A. R. (2009) A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res., 69, 5210-5217.
47. Li, C., Chen, K., Liu, Z. et al. (2008) Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J. Invest. Dermatol., 128, 1585-1588.
48. Goode, E. L., Fridley, B. L., Vierkant, R. A. et al. (2009) Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Cancer Epidemiol. Biomarkers Prev., 18, 935-944.
49. Valentin, M. D., Canalle, R., Queiroz Rde, P. and Tone, L. G. (2009) Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors. Sao Paulo Med. J., 127, 288-294.
50. Hsieh, Y. Y., Chang, C. C., Bau, D. T., Tsai, F. J., Tsai, C. H. and Chen, C. P. (2009) The p21 codon 31*C- and DRD2 codon 313*T-related genotypes/alleles, but not XRCC1 codon 399, hOGG1 codon 326, and DRD1-48 polymorphisms, are correlated with the presence of leiomyoma. Fertil. Steril., 91, 869-877.
51. Chen, J., Amos, C. I., Merriman, K. W., Wei, Q., Sen, S., Killary, A. M. and Frazier, M. L. (2010) Genetic variants of p21 and p27 and pancreatic cancer risk in non-Hispanic Whites: a case-control study. Pancreas, 39, 1-4.
52. Chung, C. J., Huang, C. J., Pu, Y. S., Su, C. T., Huang, Y. K., Chen, Y. T. and Hsueh, Y. M. (2008) Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol. Appl. Pharmacol., 232, 203-209.
53. Rajaraman, P., Wang, S. S., Rothman, N. et al. (2007) Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol. Biomarkers Prev., 16, 1655-1661.
54. Huang, S. P., Wu, W. J., Chang, W. S. et al. (2004) p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 2217-2224.
55. Tsai, M. H., Chen, W. C. and Tsai, F. J. (2002) Correlation of p21 gene codon 31 polymorphism and TNF-a gene polymorphism with nasopharyngeal carcinoma. J. Clin. Lab. Anal., 16, 146-150.
56. Chen, W. C., Wu, H. C., Hsu, C. D., Chen, H. Y. and Tsai, F. J. (2002) p21 gene codon 31 polymorphism is associated with bladder cancer. Urol. Oncol., 7, 63-66.
57. Qiu, L. X., Zhang, J., Zhu, X. D. et al. (2010) The p21 Ser31Arg polymorphism and breast cancer risk: a meta-analysis involving 51,236 subjects. Breast Cancer Res. Treat., 124, 475-479.
58. Higgins, J. P. and Thompson, S. G. (2002) Quantifying heterogeneity in a meta-analysis. Stat. Med., 21, 1539-1558.
59. Mantel, N. and Haenszel, W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl Cancer Inst., 22, 719-748.
60. DerSimonian, R. and Laird, N. (1986) Meta-analysis in clinical trials. Control. Clin. Trials., 7, 177-188.
61. Begg, C. B. and Mazumdar, M. (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-1101.
62. Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-634. (Pubitemid 27387172)
63. Wacholder, S., Chanock, S. and Garcia-Closas, M. (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl Cancer Inst., 96, 434-442. (Pubitemid 38443646)
64. Cohen, S. M., Shirai, T. and Steineck, G. (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand. J. Urol. Nephrol. Suppl., 205, 105-115.
65. Wei, Q., Cheng, L., Amos, C. I., Wang, L. E., Guo, Z., Hong, W. K. and Spitz, M. R. (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J. Natl Cancer Inst., 92, 1764-1772.
66. Zeidel, A., Beilin, B., Yardeni, I., Mayburd, E., Smirnov, G. and Bessler, H. (2002) Immune response in asymptomatic smokers. Acta Anaesthesiol. Scand., 46, 959-964.
67. Yin, M., Yan, J., Wei, S. and Wei, Q. (2010) CASP8 polymorphisms contribute to cancer susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. Carcinogenesis, 31, 850-857.
68. Zhang, Z., Xue, H., Gong, W., Wang, M., Yuan, L., Han, S. and Zhang, Z. (2009) FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis, 30, 487-493.